Drugs in ATC Class A07EA

Up to Top Level ATC Classes

Up to A - Alimentary tract and metabolism

Up to A07 - ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS

Up to A07E - INTESTINAL ANTIINFLAMMATORY AGENTS

Drugs in ATC Class: A07EA - Corticosteroids acting locally

Tradename	Generic Name
CHLOROPTIC-P S.O.P.	chloramphenicol; prednisolone
DEPO-MEDROL	methylprednisolone acetate
MEDROL	methylprednisolone acetate
PRED-G	gentamicin sulfate; prednisolone acetate

A07EA Market Analysis and Financial Projection

The ATC class A07EA (corticosteroids acting locally) represents a critical segment of anti-inflammatory medications targeting intestinal disorders like Crohn’s disease, ulcerative colitis, and eosinophilic esophagitis. This class includes agents such as budesonide, prednisolone, hydrocortisone, and betamethasone, which are designed to act locally with minimal systemic absorption[1][2][4]. Below is an analysis of the market dynamics and patent landscape for this drug class.

---

Market Dynamics

Key Players and Competition

• Budesonide dominates the A07EA market, with 15 branded drugs and 36 approved NDAs (New Drug Applications) from major pharmaceutical companies like AstraZeneca, Teva, Sun Pharma, and Mylan[3].
• Generic competition is intensifying: Budesonide faces competition from 43 suppliers and 67 bulk API vendors, driven by five Paragraph IV patent challenges[3].
• Regional trends: In Latvia and the Baltic states, A07EA drugs accounted for ~13.7% of alimentary tract medicine sales in 2015, highlighting steady demand[5][6]. Pricing varies regionally, with Latvia reporting a 5% price increase for registered drugs in 2017[5].

Clinical and Financial Trajectory

• Clinical trials: Budesonide alone has 433 active clinical trials, including Phase 4 studies for new indications like eosinophilic esophagitis and IgA nephropathy[3].
• Revenue drivers: Innovation in formulations (e.g., sublingual budesonide) and extended patents protect revenue streams, though generics pressure margins[2][3].

Factor	Impact
Generic competition	High (43 suppliers for budesonide)[3]
Regional market growth	Moderate (Baltic markets show stable consumption)[5][6]
Pricing trends	Mixed (registered drugs ↑5% in Latvia; non-registered ↓8% in 2017)[5]

---

Patent Landscape

Key Patents and Innovations

• Budesonide is protected by 37 U.S. patents and 155 international patents, with formulations for Crohn’s disease and eosinophilic esophagitis being major focal points[3][4].
• Targeted delivery mechanisms: Patents cover oral and sublingual forms to enhance local efficacy while reducing systemic exposure[2][4].
• Other A07EA drugs:
  • Prednisone: 8 patents, primarily for inflammatory bowel disease[11].
  • Hydrocortisone: 9 patents, including rectal foams and enemas[12].

Challenges and Litigation

• Paragraph IV challenges: Budesonide faces five such cases, indicating active generic encroachment[3].
• Patent expiration waves: Budesonide’s patent family spans 32 countries, with generics already entering markets in India and Europe[3].

---

Strategic Insights

• Innovation focus: Companies are investing in novel delivery systems (e.g., multi-matrix tablets) and expanded indications to differentiate products[2][3].
• Regional opportunities: Emerging markets in Eastern Europe and Asia show growth potential due to rising gastrointestinal disorder prevalence[5][6].
• Risks: Price erosion from generics and regulatory hurdles for new formulations could constrain revenue[3][5].

Highlight: "Oral corticosteroids with poor systemic availability ... are classified here, emphasizing their targeted action in intestinal diseases"[2].

---

Key Takeaways

1. A07EA is a niche but stable market, driven by chronic gastrointestinal conditions.
2. Budesonide’s strong patent portfolio offsets generic threats, but competition is rising.
3. Regional price disparities and formulation innovations shape market dynamics.

For stakeholders, balancing lifecycle management (e.g., patent extensions) with cost-effective manufacturing will be critical to sustaining growth.

References

1. https://pubchem.ncbi.nlm.nih.gov/compound/Rhinocort
2. https://atcddd.fhi.no/atc_ddd_index/?code=A07EA&showdescription=yes
3. https://www.drugpatentwatch.com/p/generic-api/BUDESONIDE
4. https://atcddd.fhi.no/atc_ddd_index/?code=A07EA&showdescription=no
5. https://www.zva.gov.lv/sites/default/files/2018-05/zva-zstat-2017.pdf
6. https://vvkt.lrv.lt/media/viesa/saugykla/2023/9/nvNsI8S7K9U.pdf
7. https://patents.google.com/patent/WO2021202817A1/en
8. https://github.com/norddrg/NDMS_workmaps/blob/master/text/ice/csp.TXT
9. https://go.drugbank.com/drugs/DB00860
10. https://www.wipo.int/edocs/pubdocs/en/wipo-pub-1075-23-en-covid-19-vaccines-and-therapeutics.pdf
11. https://go.drugbank.com/drugs/DB00635
12. https://go.drugbank.com/drugs/DB00741